Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VibeX Rapid is a CE‑marked, accelerated corneal cross‑linking riboflavin solution used topically on the de-epithelialized cornea in combination with UVA irradiation (typically via the KXL system) to strengthen corneal collagen in patients with progressive keratoconus or corneal ectasia following refractive surgery.[1][4][6] It is a 0.1% riboflavin (vitamin B2 or riboflavin‑5‑phosphate) ophthalmic formulation in saline with hydroxypropyl methylcellulose (HPMC) and no dextran, designed to enhance diffusion into the corneal stroma, reduce procedure soak time, and limit corneal thinning during epithelium‑off cross‑linking.[1][5][6] As a photosensitizer, riboflavin absorbs UVA light and generates reactive oxygen species that induce covalent cross‑links between stromal collagen fibers, increasing corneal biomechanical stability and helping to halt ectatic progression rather than directly improving vision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VibeX Rapid.